Dr Ceri Morgan and Richard Lane join the Stablepharma Ltd Advisory Board at a time of growth and investment. Stablepharma Ltd is delighted to announce two new members who will join the Advisory Board with immediate effect – Richard Lane, an experienced corporate lawyer and Dr Ceri Morgan, Senior Advisor & NED, specialising in capital […]
Read More
Stablepharma Ltd, the Fridge-free Vaccine Company and BB-NCIPD Ltd (Bul Bio) European vaccine manufacturer, have signed a second agreement for the exclusive bulk supply and commercialisation of the Tetanus vaccine (SPVX06). This agreement follows a similar arrangement with Bul Bio for the Tetanus diphtheria vaccine (SPVX02) in September 2022. “As a result of this strategic […]
Read More
Stablepharma Ltd is delighted to announce that Lorena Carmona-Rodiguez is joining the Science Team at our R&D Centre in Madrid, Spain. Lorena joins ‘The Fridge-free Vaccine Company’ as Senior Scientist to specifically progress our mRNA-LNP programme. Lorena has a Master’s Degree and PhD in Molecular Biosciences from the Universidad Autónoma de Madrid. She was, until […]
Read More
It is with great sadness and regret that the Board of Stablepharma has to announce the unexpected passing of Martin Powell on the 1st of May 2023. As our colleague and fellow Director, Martin was someone who made substantial contributions to the company since the early days and we will all miss his company, enthusiasm […]
Read More
Professor Saul Faust, consultant paediatrician at University Hospital Southampton, has been recognised for his research into vaccines which helped determine how safe and effective they were before being rolled out. He was presented the accolade by the Prince of Wales last week after it was announced last year in the Queen’s Jubilee Honour’s List. Southampton […]
Read More
Stablepharma considers IPO, Series B round to bring vaccines to market – CEO 08:00 CEST, 5 April 2023 Stablepharma, a UK developer of the world’s first fridge-free vaccines, is evaluating an IPO and a financing round to bring two vaccines to market, CEO Özgür Tuncer told Mergermarket. The business will take a decision after the summer […]
Read More
Stablepharma Ltd closed Series A funding round of $6.4m to progress the development of fridge-free vaccines and mRNA/LNP stabilisation technologies. Stablepharma Ltd, the Fridge-Free Vaccine Company closed their Series A funding round having secured a two-part £5.2m / $6.4m in total. Lead investors are Hamilton Portfolio & Oval Investments, along with CrowdCube and backing of […]
Read More
We are delighted to announce that Johnny Sutton, founder and CEO of Oval Investments, will become a member of the Board of Stablepharma Ltd. Johnny joins the Board of the ‘Fridge-free Vaccine Company’, following Oval Investments’ major participation in the Series A fundraise, recently completed on 31st October 2022. https://stablepharma.com/team/johnny-sutton/ With extensive experience within Investment […]
Read More
Stablepharma Ltd, the Fridge-free Vaccine Company and BB-NCIPD Ltd (Bul Bio) are delighted to announce that we have signed a definitive agreement for the exclusive bulk supply and commercialisation of the Tetanus diphtheria vaccine, on September 20th, 2022. This agreement follows the head of terms signed in 2022 and consolidates the relationship between Stablepharma Ltd […]
Read More
Stablepharma and BB-NCIPD Ltd (Bul Bio) establish thermostability of StablevaX™-Td Vaccine After Exposure to +45°C for 12 months In-vitro and In-vivo Studies Pave the Way for Fridge-Free Vaccines Stablepharma Ltd and BB-NCIPD Ltd (Bul Bio) formed a strategic partnership in 2021 to produce the world’s first fridge-free Tetanus diphtheria (Td) vaccine, StablevaX™-Td. Encouraging potency and […]
Read More